JP2022505841A5 - - Google Patents

Info

Publication number
JP2022505841A5
JP2022505841A5 JP2021522518A JP2021522518A JP2022505841A5 JP 2022505841 A5 JP2022505841 A5 JP 2022505841A5 JP 2021522518 A JP2021522518 A JP 2021522518A JP 2021522518 A JP2021522518 A JP 2021522518A JP 2022505841 A5 JP2022505841 A5 JP 2022505841A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021522518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505841A (ja
JP7398448B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059020 external-priority patent/WO2020084492A1/en
Publication of JP2022505841A publication Critical patent/JP2022505841A/ja
Publication of JP2022505841A5 publication Critical patent/JP2022505841A5/ja
Application granted granted Critical
Publication of JP7398448B2 publication Critical patent/JP7398448B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021522518A 2018-10-24 2019-10-22 ヒト免疫不全ウイルス複製の阻害剤 Active JP7398448B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749818P 2018-10-24 2018-10-24
US62/749,818 2018-10-24
PCT/IB2019/059020 WO2020084492A1 (en) 2018-10-24 2019-10-22 Inhibitors of human immunodeficiency virus replication

Publications (3)

Publication Number Publication Date
JP2022505841A JP2022505841A (ja) 2022-01-14
JP2022505841A5 true JP2022505841A5 (cg-RX-API-DMAC7.html) 2022-10-07
JP7398448B2 JP7398448B2 (ja) 2023-12-14

Family

ID=68344933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021522518A Active JP7398448B2 (ja) 2018-10-24 2019-10-22 ヒト免疫不全ウイルス複製の阻害剤

Country Status (25)

Country Link
US (2) US11541055B2 (cg-RX-API-DMAC7.html)
EP (1) EP3870577B1 (cg-RX-API-DMAC7.html)
JP (1) JP7398448B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210084508A (cg-RX-API-DMAC7.html)
CN (1) CN113195475A (cg-RX-API-DMAC7.html)
AR (1) AR116798A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019364739B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021007362A2 (cg-RX-API-DMAC7.html)
CA (1) CA3117289A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001025A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021004679A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210207A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000062A (cg-RX-API-DMAC7.html)
EA (1) EA202190854A1 (cg-RX-API-DMAC7.html)
ES (1) ES3026145T3 (cg-RX-API-DMAC7.html)
IL (1) IL282240B2 (cg-RX-API-DMAC7.html)
MA (1) MA53973A (cg-RX-API-DMAC7.html)
MX (1) MX2021004593A (cg-RX-API-DMAC7.html)
PE (1) PE20211781A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550813A1 (cg-RX-API-DMAC7.html)
PL (1) PL3870577T3 (cg-RX-API-DMAC7.html)
PT (1) PT3870577T (cg-RX-API-DMAC7.html)
SG (1) SG11202103560YA (cg-RX-API-DMAC7.html)
TW (1) TWI824041B (cg-RX-API-DMAC7.html)
WO (1) WO2020084492A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
MA53973A (fr) * 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
EP3986561B1 (en) * 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
WO2021070054A1 (en) * 2019-10-08 2021-04-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US12564595B2 (en) 2019-11-28 2026-03-03 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
EP4135702B1 (en) * 2020-04-15 2026-06-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
AU2022362855B2 (en) * 2021-10-13 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
US20250099464A1 (en) 2023-09-27 2025-03-27 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
AU2023466962A1 (en) 2023-09-27 2026-03-12 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037796A1 (en) 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
JP2012201642A (ja) * 2011-03-25 2012-10-22 Tsutomu Takeuchi 1−フェニルピロリジン−2,5−ジオン誘導体を有効成分とするbaffの結合阻害剤
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2016033009A1 (en) * 2014-08-27 2016-03-03 Bristol-Myers Squibb Company Imidazo[1,2-a]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication
US9873680B2 (en) * 2014-08-29 2018-01-23 Gilead Sciences, Inc. Therapeutic compounds
LT3347352T (lt) 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
CA3108633A1 (en) 2018-08-09 2020-02-13 Viiv Healthcare Uk (No 5) Limited Inhibitors of human immunodeficiency virus replication
JP7361766B2 (ja) 2018-09-14 2023-10-16 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
WO2020058844A1 (en) 2018-09-20 2020-03-26 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
FR3086760A1 (fr) 2018-10-02 2020-04-03 Institut Mines Telecom Procede d'evaluation de la resistance mecanique d'un echantillon de tissu biologique
WO2020084491A1 (en) 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
MA53973A (fr) * 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
PT3870575T (pt) 2018-10-25 2023-05-12 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
ES2969030T3 (es) 2018-10-29 2024-05-16 Viiv Healthcare Uk No 5 Ltd Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana
JP2022506399A (ja) 2018-11-05 2022-01-17 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
US20210395248A1 (en) 2018-11-05 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
US11429555B2 (en) 2019-02-26 2022-08-30 Apple Inc. Coprocessors with bypass optimization, variable grid architecture, and fused vector operations
EP3749105A4 (en) 2019-04-11 2021-10-06 Goli Nutrition Inc. FOOD SUPPLEMENT MADE OF APPLE CIDERED VINEGAR
US20220211704A1 (en) 2019-04-30 2022-07-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
EP3986561B1 (en) 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
EP4038068A1 (en) 2019-10-01 2022-08-10 VIIV Healthcare UK (No.5) Limited N-substituted-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
ES2974657T3 (es) 2019-10-01 2024-07-01 Viiv Healthcare Uk No 5 Ltd Derivados de n-substituido-6-oxo-1,6-dihidropirimidina-2-ilo como inhibidores de la replicación del virus de inmunodeficiencia humana
TW202128648A (zh) 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
US12703699B2 (en) 2020-03-06 2026-08-11 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication

Similar Documents

Publication Publication Date Title
JP2022505597A5 (cg-RX-API-DMAC7.html)
JP2022501370A5 (cg-RX-API-DMAC7.html)
JP2022505637A5 (cg-RX-API-DMAC7.html)
JP2022500425A5 (cg-RX-API-DMAC7.html)
JP2022505989A5 (cg-RX-API-DMAC7.html)
JP2024543983A5 (cg-RX-API-DMAC7.html)
JP2025071130A5 (cg-RX-API-DMAC7.html)
JP2019500387A5 (cg-RX-API-DMAC7.html)
JP2022141835A5 (cg-RX-API-DMAC7.html)
JP2022547558A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2024173998A5 (cg-RX-API-DMAC7.html)
RU2009102278A (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
JP2016527217A5 (cg-RX-API-DMAC7.html)
JP2016525102A5 (cg-RX-API-DMAC7.html)
RU2003137561A (ru) 4-замещенные нуклеозиды
JP2013209405A5 (cg-RX-API-DMAC7.html)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2019501879A5 (cg-RX-API-DMAC7.html)
JP2020512337A5 (cg-RX-API-DMAC7.html)
JP2023544716A5 (cg-RX-API-DMAC7.html)
JP2022527556A5 (cg-RX-API-DMAC7.html)
JP2011509302A5 (cg-RX-API-DMAC7.html)
IL257240A (en) History of 5– (n– benzyl tetrahydroisoquinoline – 6 – il) Pyridine – 3 – il Acetic acid as inhibitors of human immunodeficiency virus replication
JP2018522927A5 (cg-RX-API-DMAC7.html)